Barclays’s Monopar Therapeutics MNPR Stock Holding History
Bought
Maintained
Sold
Other funds holding MNPR
SVCM
SL
Barclays's MNPR Position: Q3 2026 in Review
Barclays reduced its Monopar Therapeutics (MNPR) stake by 68% in Q3 2026, selling an estimated $423K and leaving 1,893 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #4123.
Barclays first reported a position in MNPR in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.37M in Q1 2026. 106 funds tracked by Wall St. Rank hold MNPR as of Q3 2026.
- Barclays held 1,893 shares of Monopar Therapeutics worth $151K as of Q3 2026.
- Barclays sold 3,940 Monopar Therapeutics shares in Q3 2026, an estimated $423K.
- Monopar Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4123 holding.
- Barclays first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 7 quarters since.
- Barclays's Monopar Therapeutics position peaked at $1.37M in Q1 2026.
- 106 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.